Clinical trials / NCT06736262
NCT06736262Phase 2Terminated

A Phase 2, Open-Label, Extension Study to Evaluate Long Term Safety and Clinical Activity of Briquilimab in Participants From Jasper-Sponsored Chronic Urticaria Trials

Study sponsor: Jasper Therapeutics, Inc. · JSPR

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov recordCSV export · Pro
Primary completion2026-07-21Actual
Enrollment · participants67Actual
Source updated2026-08-06Last update listed in the registry record
Version history

Changes to this trial

Last 12 months
Pro unlocks the full available history and CSV export. View Pro features

· 3 fields changed

Completion date type changed

− Before

Estimated

+ After

Actual

Primary completion date changed

− Before

13 Aug 2026

+ After

21 Jul 2026

Recruitment status changed

− Before

Active not recruiting

+ After

Terminated

Check registry source

· 4 fields changed

Participant count type changed

− Before

Estimated

+ After

Actual

Enrollment · participant count changed

− Before

90 participants (planned)

+ After

67 participants (actual)

Primary completion date changed

− Before

1 Dec 2026

+ After

13 Aug 2026

Recruitment status changed

− Before

Enrolling by invitation

+ After

Active not recruiting

Check registry source